Licensing status

Publication and contact information


Peptidyl arginine deiminase type III (PADI3; PAD3) autoantibodies as a prognostic marker for rheumatoid arthritis (RA)

Patient sample studies suggest autoantibodies that recognize PAD3 and activate PAD4 (PADI4) could be used to identify patients at risk for radiographic progression in RA. Autoantibodies against PAD4 have previously been correlated with severe disease in patients with RA, but there is heterogeneity within that group. In serum samples from 150 patients with RA, 80% of those with anti-PAD3 antibodies had radiographic progression, whereas it was only 50% for those with no anti-PAD antibodies. In this patient cohort, the presence of both anti-PAD3 and anti-PAD4 antibodies was associated with increased disease severity compared with the presence of anti-PAD4 antibodies alone. Next steps include looking for anti-PAD3 and anti-PAD4 antibodies in additional patient cohorts and understanding the mechanism by which anti-PAD3 antibodies activate PAD4.

SciBX 6(24); doi:10.1038/scibx.2013.614
Published online June 20, 2013

Patent application filed; licensing status undisclosed

Darrah, E. et al. Sci. Transl. Med.; published online May 22, 2013;
Contact: Antony Rosen, The Johns Hopkins University School of Medicine, Baltimore, Md.
Contact: Felipe Andrade, same affiliation as above